Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.36 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | MGLL | Q99685 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | PHGDH | O43175 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3050164 | 0.89 | MGLL (0.37) | PAOXSIGMAR1CHRM3MGLLPHGDH | |
| SCHEMBL3051235 | 0.88 | HRH3 (0.42) | SIGMAR1ALDH1A1SMN1; SMN2 | |
| SCHEMBL7761119 | 0.85 | HPGD (0.46) | SIGMAR1CHRM3ALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL3049699 | 0.83 | HRH3 (0.45) | SIGMAR1ALDH1A1SMN1; SMN2 | |
| SCHEMBL3054073 | 0.81 | KCNH2 (0.56) | SIGMAR1 | |
| SCHEMBL3045277 | 0.81 | MC4R (0.54) | SIGMAR1ALDH1A1MGLLPHGDHPOLB | |
| SCHEMBL20332905 | 0.80 | PAOX (0.45) | PAOXSIGMAR1 | |
| SCHEMBL3759668 | 0.76 | SIGMAR1 (0.46) | SIGMAR1 | |
| SCHEMBL21634183 | 0.76 | SIGMAR1 (0.45) | PAOXSIGMAR1 | |
| SCHEMBL18024014 | 0.76 | PAOX (0.43) | PAOXSIGMAR1CHRM2CHRM4CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010025025-A1 | Novel process for the preparation of cyclosporin derivatives | AVENTIS PHARMA S.A. (FR) | 2001-09-27 | — | — | US | claimed |
| US-20100173838-A1 | NOVEL PROCESS FOR THE PREPARATION OF CYCLOSPORIN DERIVATIVES | VISKOV CHRISTIAN | 2010-07-08 | — | — | US | disclosed |
| US-7678766-B2 | Process for the preparation of cyclosporin derivatives | AVENTIS PHARMA S.A. (FR) | 2010-03-16 | — | — | US | disclosed |
| EP-1098903-B1 | METHOD FOR PREPARING CYCLOSPORIN DERIVATIVES | AVENTIS PHARMA SA (FR) | 2008-09-03 | — | — | EP | disclosed |
| US-20070213260-A1 | Novel process for the preparation of cyclosporin derivatives | AVENTIS PHARMA S.A. | 2007-09-13 | — | — | US | disclosed |
| US-7226905-B2 | Process for the preparation of cyclosporin derivatives | AVENTIS PHARMA S.A. (FR) | 2007-06-05 | — | — | US | disclosed |
| EP-0979244-B1 | NOVEL CYCLOSPORIN DERIVATIVES, PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | AVENTIS PHARMA SA (FR) | 2005-03-02 | — | — | EP | disclosed |
| EP-1040121-B1 | NOVEL METHOD FOR PREPARING CYLOSPORIN DERIVATIVES | AVENTIS PHARMA (FR) | 2004-07-21 | — | — | EP | disclosed |
| EP-0948527-B1 | CYCLOSPORIN DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | AVENTIS PHARMA SA (FR) | 2002-06-05 | — | — | EP | disclosed |
| US-20010025025-A1 | Novel process for the preparation of cyclosporin derivatives | AVENTIS PHARMA S.A. (FR) | 2001-09-27 | — | — | US | disclosed |
| EP-1098903-A1 | NOVEL METHOD FOR PREPARING CYCLOSPORIN DERIVATIVES | Aventis Pharma S.A. (FR) | 2001-05-16 | — | — | EP | disclosed |
| WO-1999067280-A1 | NOVEL METHOD FOR PREPARING CYCLOSPORIN DERIVATIVES | AVENTIS PHARMA S.A. (FR) | 1999-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213260-A1 | Novel process for the preparation of cyclosporin derivatives | MGMT, MALT1, TET2 | PAOX 4448/4885SIGMAR1 1115/4885CHRM2 3844/4885 |
| US-20010025025-A1 | Novel process for the preparation of cyclosporin derivatives | MGMT, MALT1, TET2 | PAOX 4448/4885SIGMAR1 1115/4885CHRM2 3844/4885 |
| US-20100173838-A1 | NOVEL PROCESS FOR THE PREPARATION OF CYCLOSPORIN DERIVATIVES | MGMT, MALT1, CHP1 | PAOX 4484/4885SIGMAR1 787/4885CHRM2 3832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.